OmniAb Inc Ordinary Shares OABI 深 沪
等待开盘 12-19 09:30:00 美东时间
2.01
-0.050
-2.43%
华盛通- 最 高2.15
- 今 开2.09
- 成交量 66.42万股
- 最 低 2.01
- 昨 收 2.06
- 总市值 2.89亿
- 52周最高 4.02
- 市盈率 静 --
- 换手率 0.46%
- 52周最低 1.22
- 委 比 -7.78%
- 总股本 1.44亿
- 历史最高 10.87
- 量 比 1.07
- 振 幅 6.80%
- 历史最低 1.22
- 每 手 1
- 风险率 0.76%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Platform Technologies Drive $211B Surge in Precision Cancer Treatment
Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Dec. 11, 2025 /PRNewswire/ -- Equity Insider News Commentary – November's wave of FDA oncology approvals signals the industry's shift to...
12-11 23:17
OmniAb And Arrowmark Partners Sign A License And Services Agreement For Novel OmniAb-Derived Antibody Discovery Programs With Mabtrx Biosciences; OmniAb To Receive Revenue For Discovery Services As Well As Potential Equity And Royalties
OmniAb, Inc. (NASDAQ:OABI) and ArrowMark Partners ("ArrowMark") today announced the signing of a license and services agreement for novel OmniAb-derived antibody discovery programs with Mabtrx Biosciences, a wholly owned
11-18 06:28
Earnings Scheduled For November 4, 2025
Companies Reporting Before The Bell • Sequans Communications (NYSE:SQNS) is lik...
11-04 19:12
Top 3 Health Care Stocks You'll Regret Missing This Quarter
The most oversold stocks in the health care sector presents an opportunity to b...
08-26 19:12
OmniAb to raise $30M in private stock placement
OmniAb (NASDAQ:OABI) has entered into a definitive agreement for a private placement of its common stock to raise approximately $30 million in gross proceeds. The company will issue and sell a total o...
08-25 19:34
OmniAb Announces $30M Private Placement Agreement
An update from OmniAb ( ($OABI) ) is now available. On August 24, 2025, OmniAb,...
08-25 19:28
A Look Ahead: Rapid Micro Biosystems's Earnings Forecast
Rapid Micro Biosystems (NASDAQ:RPID) is gearing up to announce its quarterly ea...
08-12 02:01
RBC Capital Maintains Outperform on OmniAb, Lowers Price Target to $3
RBC Capital analyst Conor McNamara maintains OmniAb (NASDAQ:OABI) with a Outperform and lowers the price target from $4 to $3.
08-07 23:11
CORRECTION: OmniAb Q2 EPS $(0.15) Beats $(0.16) Estimate, Sales $3.897M Miss $5.334M Estimate
OmniAb (NASDAQ:OABI) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.16) by 4.46 percent. This is a 15.38 percent decrease over losses of $(0.13) per share from the same
08-07 06:51
OmniAb Affirms FY2025 Sales Guidance of $20.000M-$25.000M vs $22.970M Est
OmniAb (NASDAQ:OABI) affirms FY2025 sales outlook from $20.000 million-$25.000 million to $20.000 million-$25.000 million vs $22.970 million estimate.
08-07 05:54
